Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. - Wikidata - wikimedia - TriplyDB

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

http://www.wikidata.org/entity/Q37071001

about

Identification and characterization of potential therapeutic candidates in emerging human pathogen Mycobacterium abscessus: a novel hierarchical in silico approach Network pharmacology-based identification of key pharmacological pathways of Yin-Huang-Qing-Fei capsule acting on chronic bronchitis Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life Moxifloxacin safety: an analysis of 14 years of clinical data.Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology.Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease Improved HPLC method for the determination of moxifloxacin in application to a pharmacokinetics study in patients with infectious diseases.

P2860

Q28488335-F41AD433-541C-43A4-BDF3-C70B4520358A Q28818549-530479B5-D7CB-48C0-B69D-ACA68F568C23 Q33755801-9E835DB3-D86F-45F8-B8DC-55AB4067B61F Q34310568-5C302DC8-EA3B-4A02-A235-9E6921DC20AC Q34560033-D0F88733-0491-4A60-B2E4-7562D619137F Q35096997-FF721750-17BF-4F41-93C7-C7EAB9631804 Q36087058-6899673F-B920-44ED-882E-5C5C5A2841B4 Q37023332-7468465C-8F10-4373-9AD8-9070C8698F10 Q41790812-A925D2AD-775A-4CEA-98FC-F8ACFD1FC84E

P2860

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

http://www.wikidata.org/entity/Q37071001

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

@en

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

@nl

type

label

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

@en

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

@nl

prefLabel

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

@en

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

@nl

P1433

Q37071001-D5DDCDAC-63FB-4C15-8D35-E810037C552D

P1476

Q37071001-D533C451-862F-4890-B5CB-40980A21DC55

P2093

Q37071001-64605B2E-2DB7-49C0-A748-937E72240237

P2860

Q37071001-0D19CE12-78B8-43CC-89BB-D56D03993A57

Q37071001-1B96248F-692A-4C20-B911-784F51F9814F

Q37071001-1DA71F29-05BA-42FE-B418-43D5825FE736

Q37071001-1FE4710E-B42E-411A-AAA0-579E57C89865

Q37071001-2A31369B-52F5-4C74-9B4F-EA277986169D

Q37071001-2F7AD7AD-0DFB-44C7-8E3C-FB36B61C368F

Q37071001-356A453D-0082-4FB8-8C2C-CF6982F63EC8

Q37071001-37FA297A-27F4-4F79-8EB1-92F761DC373D

Q37071001-3CD166E8-4FA2-4F71-BB73-56724E2CB219

Q37071001-3F701F29-E067-4A32-8B2F-6F77714A49F6

P304

Q37071001-42F2FC66-5603-4F15-96A6-C6592A4DB498

P31

Q37071001-C8E08047-3E12-4B88-907E-B5132835B3C4

P407

Q37071001-A2DAB33A-5CDE-4833-8B97-2CA8EB280CE6

P433

Q37071001-17989A4D-251E-47DE-8798-090D1459BB92

P478

Q37071001-963F77CB-971C-4AEC-BEDE-6638D1ED3B7A

P50

Q37071001-960192BB-1AED-42CA-A44C-02885E4B7C5D

P577

Q37071001-4088943A-A6B6-4E21-A10B-30734465B866

P698

Q37071001-214932DE-23AF-4AC0-9D81-F04985B9788A

P921

Q37071001-5F68EBB3-1FDD-4307-A12F-E177B43BA4B3

Q37071001-AE903BC3-1C33-4204-A6FD-1B3511BC68F5

Q37071001-B3E0ED00-57A6-44FA-89C9-B404683BE3BF

P932

Q37071001-D6BBE004-63BB-44AC-BB32-73D99EBDDF3C

P1433

International Journal of Chronic Obstructive Pulmonary Disease

P1476

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD

@en

P2093

Marc Miravitlles

http://www.w3.org/2001/XMLSchema#string

P2860

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

In vitro activity of BAY 12-8039, a new fluoroquinolone

Maintaining fluoroquinolone class efficacy: review of influencing factors.

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.

Antibiotic use in patients admitted with acute exacerbations of chronic obstructive pulmonary disease.

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.

Evaluation of the clinical microbiology profile of moxifloxacin.

Does short-course antibiotic therapy better meet patient expectations?

Canadian guidelines for the management of acute exacerbations of chronic bronchitis.

P304

191-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Marc Miravitlles

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18229559

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

2695197

http://www.w3.org/2001/XMLSchema#string